** Drug developer ARS Pharmaceuticals' SPRY.O shares rise 18.8% to $13.84
** Co reports Q4 net income of $49.9 million vs. loss estimate of $14.4 million, according to data compiled by LSEG
** Co posts Q4 revenue of $86.6 million, beating analysts' estimates of $15.8 million
** Profit boosted by partnership revenue from drug developer ALK-Abelló to commercialise allergic reaction nasal spray, neffy, in Europe, Canada and outside of U.S.
** SPRY received a non-refundable, upfront cash payment of $145 million from ALK and, of the total cash payment, $73.5 million was included in SPRY's Q4 revenue
** Up to last close, SPRY had risen 37.7% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。